FDA review remains neutral on boosters ahead of critical Friday vote even as Pfizer pushes additional shots

A highly-anticipated Food and Drug Administration review of evidence on whether a booster shot of the Pfizer-BioNTech coronavirus vaccine is widely necessary struck a noncommittal tone Wednesday.

View original article
Contributor: Carolyn Y. Johnson